Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Anthony @ Equity Investigations, Dear Anthony, -- Ignore unavailable to you. Want to Upgrade?

To: Anthony@Pacific who wrote (50588)	1/24/2000 4:46:00 PM
From: johnsto1	Respond to of 122087

Anthony.You like POCI here at all? This one sure is wound up tight with 3.2 float;24% institutionally held in the exploding dwdm market.

To: Anthony@Pacific who wrote (50588)	1/24/2000 4:51:00 PM
From: Anthony@Pacific	Read Replies (4) \| Respond to of 122087

VASO<----some important follow up; WESTBURY, N.Y. (Dow Jones)--Articles recently published in the New England Journal of Medicine and other medical journals suggest that Vasomedical Inc.'s (VASO) enhanced external counterpulsation, or EECP, therapy for angina patients should be considered before transmyocardial revascularization. In a press release Monday, the company said articles published in Clinical Cardiology, Harvard Heart Watch and HealthNews all commented that patients should try less-invasive therapy's, including EECP, before transmyocardial revascularization. Shares of Vasomedical were trading up 9/32,or 29%, at 1 1/4 on volume of about 1.6 million shares. The company's average daily volume is 216,007 shares. Vasomedical is engaged in designing, manufacturing, marketing and supporting external counterpulsation systems. -Charlie Dougiello; Dow Jones Newswires; 201-938-5388